Hematology Division, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Cold Spring Harb Perspect Med. 2023 Jan 3;13(1):a041174. doi: 10.1101/cshperspect.a041174.
The formation of new blood and lymphatic vessels is essential for both the development of multicellular organisms and (patho)physiological processes like wound repair and tumor growth. In the 1990s, circulating blood platelets were first postulated to regulate tumor angiogenesis by interacting with the endothelium and releasing angiogenic regulators from specialized α granules. Since then, many studies have validated the contributions of platelets to tumor angiogenesis, while uncovering novel roles for platelets in other angiogenic processes like wound resolution and retinal vascular disease. Although the majority of (lymph)angiogenesis occurs during development, platelets appear necessary for lymphatic but not vascular growth, implying their particular importance in pathological cases of adult angiogenesis. Future work is required to determine whether drugs targeting platelet production or function offer a clinically relevant tool to limit detrimental angiogenesis.
新的血液和淋巴管的形成对于多细胞生物的发育以及(病理)生理过程,如伤口修复和肿瘤生长,都是必不可少的。在 20 世纪 90 年代,人们首次提出循环血小板通过与内皮细胞相互作用并从专门的α颗粒中释放血管生成调节剂来调节肿瘤血管生成。从那时起,许多研究已经验证了血小板对肿瘤血管生成的贡献,同时揭示了血小板在其他血管生成过程中的新作用,如伤口愈合和视网膜血管疾病。虽然(淋)血管生成的大部分发生在发育过程中,但血小板似乎对淋巴管而非血管的生长是必需的,这表明它们在成年血管生成的病理性病例中特别重要。未来的工作需要确定针对血小板产生或功能的药物是否提供了一种具有临床相关性的工具来限制有害的血管生成。